Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin +/- Cetuximab in Urothelial Carcinoma
NCT00645593Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2008
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in urothelial carcinoma (UC), sponsored by University of Michigan Rogel Cancer Center. Started Mar 2008; status: completed.
02
Drugs
KL-140
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00645593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645593.